InvestSMART

4DMedical Limited (ASX:4DX)

ALERT: Price-sensitive ASX Announcement for 4DX
Current share price for 4DX : $3.970 1.86 (88.15%)+
Announcement
Release
3 Oct 2025 9:56AM
Price at Release
$2.110
Full Release
download
Summary
4DMedical Limited has announced securing $22.6 million through the exercise of deep in-the-money options, with 99.7% of the 4DXOA Options exercised at an exercise price of $0.55. The company's pro forma cash balance as of 30 June 2025 stands at $45.5 million, bolstered by a $10 million strategic investment from Pro Medicus and a $6 million R&D Tax Incentive receipt. This funding will support the commercialization and adoption of 4DMedical's CT:VQ™ technology, extending into the U.S. healthcare market in partnership with Philips. The company also highlights the potential for further capital inflows through additional in-the-money options (ASX:4DXO) that could provide up to $30.2 million to the balance sheet. These financial developments position 4DMedical to advance their strategic goals, including further research and product development.
Key Points
  • 4DMedical secures $22.6 million through exercise of options.
  • 99.7% of 4DXOA Options exercised at $0.55.
  • Pro forma cash balance of $45.5 million as of June 30, 2025.
  • $10 million investment from Pro Medicus and $6 million R&D Tax Incentive.
  • Funding to support commercialization of CT:VQ™ technology.
  • Further capital inflows possible through additional in-the-money options.
  • Strategic focus on U.S. healthcare market with Philips agreement.
  • Commitment to ongoing research and development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.